Fate Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $2,082 | $1,299 | $1,369 | $1,741 |
Gross Profit | 2,082 | -1,619 | 1,369 | -24,097 |
EBITDA | -30,554 | -28,295 | -29,311 | -29,023 |
EBIT | -31,213 | -32,374 | -32,250 | |
Net Income | -30,159 | -31,213 | -32,374 | -32,250 |
Net Change In Cash | 2,082 | 1,299 | 1,369 | 1,741 |
Free Cash Flow | -23,514 | -31,061 | -24,506 | -26,577 |
Cash | 32,429 | 39,570 | 46,628 | 40,622 |
Basic Shares | 120,397 | 120,030 | 118,789 | 118,998 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $6,646 | $13,631 | $63,533 | $96,300 |
Gross Profit | -6,255 | -104,900 | -93,654 | 96,300 |
EBITDA | -127,020 | -176,577 | -142,646 | -294,628 |
EBIT | -136,315 | -195,539 | -160,928 | -308,386 |
Net Income | -136,315 | -186,262 | -160,928 | -255,056 |
Net Change In Cash | 6,646 | 13,631 | 63,533 | 96,300 |
Free Cash Flow | -112,037 | -123,604 | -138,416 | -283,774 |
Cash | 46,628 | 36,056 | 41,870 | 61,333 |
Basic Shares | 118,789 | 113,685 | 98,411 | 96,826 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.25 |
2026-03-31 | -$0.26 |
2025-12-31 | -$0.27 |
2025-09-30 | -$0.27 |